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Background/aim: The canonical Wingless-type (WNT) pathway is involved in normal hematopoietic cell development and deregulated
WNT signaling is implicated in the development of hematological malignancies. Dickkopf 1 (DKK1) acts as a modulator of the
β-catenin regulated canonical pathway. Activation of DKK1 leads to apoptosis and growth suppression, whereas silencing by promoter
hypermethylation results in abnormal WNT activation. The secreted inhibitor Dickkopf can antagonize WNT signaling by competitively
binding to low density lipoprotein receptors (LRPs) 5 and 6.
Materials and methods: We studied DKK1 gene promoter methylation and investigated DKK1, β-catenin, LRP5, and LRP6 mRNA
levels in B-cell acute lymphoblastic leukemia (B-ALL) patients (n = 90). Methylation-specific PCR and bisulfite sequencing were used
for methylation profiling and quantitative real-time PCR was used for mRNA detection.
Results: The DKK1 gene was examined for its promoter methylation and only 33% of patients were found methylated. On the other
hand, B-ALL cases showed high expression of DKK1 (P = 0.01), LRP5 (P = 0.04), and LRP6 (P = 0.02) compared to normal bone marrow
cells.
Conclusion: DKK1 methylation exists in some of cases but is not sufficient for WNT pathway activation alone in pediatric B-ALL.
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1. Introduction
WNT signals play a role in the self-renewal of
hematopoietic stem cells and T- and B-lymphocyte
development. WNT antagonists are active components in
tuning WNT signals (1). The DKK family encodes secreted
proteins that antagonize β-catenin regulated signaling by
inhibiting the WNT coreceptors Lrp5 and Lrp6. The Dkk1
protein binds to Lrps and leads to the disassociation of
Lrp-5/6 from frizzled receptors (Fz), which are the specific
receptors of WNT ligands that prevent the formation of
a functional WNT receptor complex. DKK1 is the most
extensively studied Dickkopf family member. Different
levels of expression in tumor cell lines or tissues were
shown. Elevated levels of DKK1 are found to influence
several important steps in the mobilization, engraftment,
and proliferation of hematopoietic stem cells (2). Tian et
al. showed that short-term exposure to low levels of Dkk1
induces moderate proliferation of mesenchymal stem cells,
whereas long-term exposure to high levels of Dkk1 causes
a loss of cell viability (2). Additionally, DKK1 has also been
* Correspondence: mugeay@istanbul.edu.tr

identified as a potential target gene of p53. Evidence of
a p53 binding site in the promoter region of DKK1 and
its induction may mediate p53 tumor suppression by
antagonizing the WNT signaling pathway (3).
DKK1 has been reported as a tumor suppressor gene
and promoter methylations were found in several human
cancers such as gastrointestinal cancer (4), cervical cancer
(5), and breast cancer (6), as well as leukemias. DKK3
gene hypermethylation is reported in acute lymphoblastic
leukemia (ALL) and a correlation was found with good
prognosis in T-cell ALL patients (7). Suzuki et al. revealed
that DKK1 methylation is involved in leukemogenesis
and can be used as a prognostic marker in acute myeloid
leukemia (AML) (8). Impairment of the DKK1 gene by
genetic and epigenetic mechanisms may also accompany
blastic transformation in ALL. This idea generated our
study to investigate the DKK1 expression and promoter
methylation status in pediatric ALL patients and its
relationship with the WNT cascade partners LRP5 and
LRP6.

357

FIRTINA et al. / Turk J Med Sci
2. Materials and methods
2.1. Patients and controls
A total of 90 pediatric B-cell acute lymphoblastic leukemia
(B-ALL) patients who diagnosed at the İstanbul and
Cerrahpaşa Medical Faculties of İstanbul University
were included in this study. Bone marrow samples were
obtained at the time of diagnosis. Patients were diagnosed
according to the criteria of the French-American-British
(FAB) group. The median age was 10.0 years (min. 1
month, max. 16 years) and the median WBC count was
33 × 109/L (min. 1, max. 600). Twelve of the patients were
translocations carriers; 5 of them were t(12;21)-positive, 4
of them were t(4;11)-positive, and 3 of them were t(9;22)positive. Additional clinical features such as tumor lysis
(n = 6), lymphadenopathy (n = 22), splenomegaly (n =
47), and hepatomegaly (n = 43) were detected among the
patients. In addition to B-ALL patients, a group of T-ALL
(n = 15) patient samples, a B-ALL cell line (FLEB 14-4),
and three T-ALL (MOLT4, JURKAT, and TALL-1) cell
lines were also examined.
Sixteen healthy peripheral blood samples, normal bone
marrow (n = 6), total thymus tissue, and CD19-positive
cells were used as control groups. To obtain CD19-positive
cells, mononuclear cells were isolated from 5 healthy
individuals and sorted by CD19-specific magnetic beads
(MACS, Miltenyi Biotech, Germany) as described by the
manufacturer. The purity was checked by flow cytometry.
The ethical committee of the İstanbul Medical Faculty
of İstanbul University approved this study and informed
consent was obtained from all patients and healthy
controls.
2.2. RNA isolation and cDNA synthesis
Bone marrow and/or peripheral blood samples were
homogenized in RTL buffer (QIAGEN GmbH, Germany).
Total RNA was isolated by the QIAGEN RNeasy Protect
Kit. RNA samples were treated using DNAse (1 U/μg)
to avoid possible DNA contamination resulting from
isolation. RNA quality and quantity were checked by 1%
ethidium bromide-stained agarose gel. cDNA synthesis
was performed by using random hexamers (Roche
Diagnostics, Mannheim, Germany) and MMLV reverse
transcriptase (MBI Fermentas, Lithuania) according to the
manufacturer’s protocol.
2.3. Analysis of gene expression by real time quantitative
RT-PCR
The expression levels of DKK1, β-catenin, LRP5, and LRP6
were detected by quantitative real-time PCR (QRT-PCR)
carried out on a LightCycler Instrument 480 (Roche
Diagnostics), with the LightCycler 480 Fast Start SYBR
Green I Master Kit (Roche Diagnostics). Primers (5 pmol)
and 200 ng of cDNA were used in each run and each
sample was studied in duplicate. The specificity of product
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amplification was confirmed by melting curve analyses
and agarose gel electrophoresis. The PCR program
was as follows: initial denaturation at 95 °C for 7 min;
amplification for 5 s at 95 °C, 10 s at 56–60 °C, and 10 s
at 72 °C for 45 cycles; and melting curve for 15 s at 60 °C
for one cycle. The 3 reference genes (β-actin, Cyclophilin,
and ABL) were used for normalization as described by
Vandesompele et al. (9).
2.4. Bisulfite treatment and methylation specific
polymerase chain reaction (MS-PCR)
Following the DNA isolation, sodium bisulfite (NaBiS)
treatment was performed as described by Frommer et al.
(10). NaBiS-treated DNA was purified by the Gene Clean
III Kit (Qbiogene, USA) according to the manufacturer’s
instructions. After the bisulfite treatment, MS-PCR was
used to amplify the promoter region of the DKK1 gene
in all samples. MethPrimer (http://www.urogene.org/
methprimer/index1.html) was used to determine the CpG
island range of the DKK1 gene and 130–300 bp and 600–
800 bp of DKK1 was found in the CpG-rich region of this
gene. Previously described primer sequences (11) and the
CpG island range of the DKK1 gene are given in Figure 1.
PCR conditions were as follows: 95 °C for 10 min for initial
denaturation; 95 °C for 30 s, 55 °C for 45 s, and 72 °C for 1
min for 35 cycles; and a final extension at 72 °C for 5 min.
PCR yields were evaluated based on methylation status
using a 3% agarose gel. One DNA sample was treated with
SssI methylase enzyme (New England Biolabs, USA) to
obtain a fully methylated positive control in each run.
2.5. Statistical analysis
Relative expressions were calculated according to the
mathematic model based on the crossing points (12).
Differences between the relative expression levels of
cases and controls were tested by Mann–Whitney U test.
Proportional differences between groups were analyzed
by chi-square (χ2) or Fisher exact tests. The correlation
between methylation status and clinical parameters (sex,
age, WBC count at diagnosis, etc.) was examined by the
use of regression analysis. The Kaplan–Meier method was
used to estimate survival rates. P ≤ 0.05 (two-sided) was
considered statistically significant. The log rank test was
used for overall survival analyses. All statistical analyses
were done with SPSS 10.0.
3. Results
3.1. DKK1 promoter methylation in cell lines and ALL
patients
To check the epigenetic changes in DKK1, the promoter
methylation status of the DKK1 promoter was analyzed
in patients, as shown in Figure 2A. B-ALL (FLEB 14-4)
and T-ALL (MOLT4, JURKAT, and TALL-1) cell lines
were found methylated. Methylation was confirmed by
methylation-specific sequencing as shown in Figure 2B.
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Figure 1. CpG island range of DKK1 promoter determined by MethPrimer program. Lighter letters represent primer sequences, v
represents CpG islands.

Thirty-three percent of the B-ALL patients (30/90) were
found methylated for the DKK1 gene and no methylation
was found in control samples (n = 15). The methylation
rate of T-ALL cases was much lower (4/14, 20%).
3.2. DKK1, LRP5, and LRP6 genes are highly expressed
in B-ALL patients
To evaluate the potential effects of hypermethylation of
the DKK1 gene, the relative mRNA levels of DKK1 and its
directly interacted genes (β-catenin, LRP5, and LRP6) were
determined in T-cell and B-cell ALL patients. Seventyone percent of B-ALL patients showed prominent DKK1
mRNA levels. Briefly, B-ALL patients showed significantly
higher DKK1 expression (P = 0.01) compared to CD19positive cells and expression levels of LRP5 (P = 0.04) and
LRP6 (P = 0.02) were found increased (Figure 3A). There
was no difference in DKK1 (P = 0.58), LRP5 (P = 0.11),
or LRP6 (P = 0.07) gene expressions in T-ALL patients
(Figure 3B). The expression levels did not differ between
B-cell and T-cell ALL patients for DKK1 (P = 0.38), LRP5
(P = 0.18), and LRP6 (P = 0.26).
3.3. Clinical correlation
Clinical and laboratory findings including sex (P = 0.97),
phenotype (P = 0.28), age (P = 1.00), WBC count at
diagnosis (P = 0.86), material (P = 0.90), translocation (P =
0.16), and outcome (P = 0.40) of the patients did not show
differences between methylated and unmethylated groups
(Table). The median follow-up was 6 years (min. 1 month,
max. 12 years). Kaplan–Meier estimate of probability of
survival according to DKK1 gene methylation existence
showed no significant difference (P = 0.60; 95% CI,

4.8–5.9). There was also no statistical difference between
methylated and unmethylated patients in 150-month
overall survival analyses (P = 0.94; Figure 4).
4. Discussion
DKK1 acts as a tumor suppressor and differential
expressions and methylations have been reported in
different cancer types (13). Methylation of DKK1 helps
to inactivate tumor suppressive apoptotic or growtharresting events and may have prognostic impacts on
B-cell and T-cell ALL (14). Our previous findings also
showed that WNT5A is highly methylated in T-ALL but
not B-ALL samples (15).
In this study, we examined DKK1 promoter
methylation status in representative cell lines and
pediatric ALL cases and showed that 33% of B-ALL
patients had promoter methylation of the DKK1 gene. The
mechanisms responsible for activation and regulation of
DKK1 expression in leukemia are not known. However,
there are some studies that propose various mechanisms
of DKK1 activation. Tumor tissues, which have high
levels of methylation, are expected to be silenced and
this presumably results in a growth advantage and clonal
expansion to the affected cells. Epigenetic changes in
the DKK1 gene could generate unexpected activating or
inactivating events.
Besides DKK1 methylation, expression levels of DKK1
were also examined in pediatric ALL. DKK1 overexpression
is shown to be a frequent finding in breast cancer (16),
mesothelioma (17), hepatoblastoma, and Wilms tumor
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Figure 2. A) DKK1 methylation status in acute leukemia patients and controls. Methylation-specific PCR (MS-PCR) results on agarose
gel electrophoresis; M: DNA ladder, IVM: in vitro methylated sample, AL1–AL6: patient samples, C1–C3: control samples. B) DKK1
gene methylation-specific PCR results in B- and T-ALL cell lines and confirmation of DKK1 methylation of FLEB 14-4 cell line by
methylation-specific sequencing.
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Figure 3. Relative DKK1, β-catenin, LRP5, and LRP6 expression levels in B-ALL and T-ALL patients and the controls (CD19-positive
cells for normal B-cell population and total thymus for normal T-cell population) by QRT-PCR.
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Table. Clinical characteristics and the methylation status of acute lymphoblastic leukemia patients.
Acute lymphoblastic leukemia patients (n = 104)
Methylated

Unmethylated

n (%)

n (%)

P-value

Male

33.30

66.60

0.97

Female

27.00

73.00

B-cell

33.70

66.30

T-cell

20.00

80.00

Children

31.50

68.50

1.00

<10 × 109 /L

12.80

24.50

0.86

9

10–50 × 10 /L

31.90

56.00

>50 × 10 /L

55.30

18.90

Bone marrow

30.60

69.30

Blood

32.00

68.00

CR

30.20

69.79

Ex

50.00

50.00

Sex

Phenotype
0.28

Age
WBC count

9

Material
0.90

Outcome
0.40

WBC, White blood cell count at diagnosis; CR, complete remission; Ex, exitus.
P < 0.05 represents a statistically significant value.

Figure 4. Overall survival analyses in ALL patients.
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patients (18). This study showed that 71% of B-ALL cases
had upregulated DKK1 gene expression. DKK1 expression
was reported to induce the proliferation of human adult
bone marrow stem cells. In adult human mesenchymal
stem cells from bone marrow stoma, high levels of DKK1
allow the cells to reenter the cell cycle by inhibiting the
canonical WNT pathway (19). In our previous study,
deregulated WNT/β-catenin signaling was shown as a
novel oncogenic event in childhood T-ALL (20), whereas
this is not the case for B-ALL patients (unpublished data).
Here, DKK1 expression was not significant in T-ALL,
supporting our previous findings due to the canonical
WNT inhibitor role of DKK1.
LRP5 and -6 proteins are essential coreceptors for the
Dickkopf antagonist function in WNT signaling. B-ALL
samples, which did not express β-catenin, have high DKK1,
LRP5, and LRP6 mRNA expressions. On the other hand, it
has been suggested that Dkk proteins might have WNTindependent functions, such as Dkk1 overexpression
inducing growth suppression (13).
Clinical features did show any association between the
expression and methylation patterns among the pediatric

acute leukemia patients. Survival analyses also did not
show any difference.
Although the mechanism(s) by which DKK1
contributes to acute leukemia is not clear, we can conclude
that Wnt involvement in T-cell and B-cell leukemia is
different. These results imply a link between genetic and
epigenetic changes during the blastic transformation in
leukemia. We may propose that DKK1 has dual functions;
expression of this gene promotes β-catenin-mediated
transcription activation and hypermethylation of DKK1
in bone marrow leukemic blasts may affect leukemia
pathogenesis by a different mechanism.
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